HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nobuhiro Nakanishi Selected Research

Nobuhiro Nakanishi Research Topics

Disease

6Hemorrhage
07/2023 - 06/2019
3Thrombosis (Thrombus)
01/2021 - 03/2020
3Type 2 Diabetes Mellitus (MODY)
01/2018 - 01/2017
2Myocardial Infarction
11/2020 - 03/2020
2Body Weight (Weight, Body)
01/2018 - 01/2017
1Chronic Limb-Threatening Ischemia
01/2022
1Thrombophilia
01/2022
1Malnutrition (Nutritional Deficiencies)
01/2022
1Fibrosis (Cirrhosis)
01/2021
1Hypertrophy
03/2020
1Infarction (Infarctions)
03/2020
1Inflammation (Inflammations)
03/2020
1Thrombocytopenia (Thrombopenia)
06/2019
1Atrial Fibrillation
01/2017
1Edema (Dropsy)
01/2017

Drug/Important Bio-Agent (IBA)

3CanagliflozinIBA
01/2018 - 01/2017
33- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA
01/2018 - 01/2017
3Glucose (Dextrose)FDA LinkGeneric
01/2018 - 01/2017
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2021 - 03/2020
2RivaroxabanIBA
11/2020 - 03/2020
2SodiumIBA
01/2018 - 01/2017
2Sodium-Glucose Transporter 2 InhibitorsIBA
01/2018 - 01/2017
2SymportersIBA
01/2018 - 01/2017
1AnticoagulantsIBA
01/2022
1Biomarkers (Surrogate Marker)IBA
01/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1Factor Xa (Coagulation Factor Xa)IBA
03/2020
1Proteinase-Activated ReceptorsIBA
03/2020
1DiureticsIBA
01/2017
1Furosemide (Lasix)FDA LinkGeneric
01/2017
1C-PeptideIBA
01/2017

Therapy/Procedure

5Therapeutics
01/2022 - 01/2017
4Percutaneous Coronary Intervention
07/2023 - 01/2021
1Renal Dialysis (Hemodialysis)
01/2021
1Transcatheter Aortic Valve Replacement
06/2019